Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables: 2021-2024

Historic Receivables for Apellis Pharmaceuticals (APLS) over the last 4 years, with Dec 2024 value amounting to $269.5 million.

  • Apellis Pharmaceuticals' Receivables rose 23.98% to $352.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 0.77%. This contributed to the annual value of $269.5 million for FY2024, which is 28.62% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Receivables of $269.5 million as of FY2024, which was up 28.62% from $209.5 million recorded in FY2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Receivables peaked at $269.5 million during FY2024, and registered a low of $9.2 million during FY2022.
  • Its 3-year average for Receivables is $162.7 million, with a median of $209.5 million in 2023.
  • In the last 5 years, Apellis Pharmaceuticals' Receivables fell by 9.24% in 2022 and then spiked by 2,184.83% in 2023.
  • Yearly analysis of 4 years shows Apellis Pharmaceuticals' Receivables stood at $10.1 million in 2021, then fell by 9.24% to $9.2 million in 2022, then spiked by 2,184.83% to $209.5 million in 2023, then climbed by 28.62% to $269.5 million in 2024.